Further to DrugAlert vol 1027, HPS Pharmacies wish to advise that the supply disruption of Apresoline® (hydralazine) 20 mg Powder for Injection is ongoing. To ensure continuity of supply, HPS Pharmacies have organised and secured S19A and SAS stock.
Distribution of the S19A stock to the wholesaler has been completed and further stock is due to arrive in late January 2026. Additionally, to ensure sufficient cover until the next batches of S19A stock arrive, SAS product has also been released and is available to order from the wholesaler.
The alternative products are as follows:
- Hydrapres® 20 mg AMP 1 mL x 5 (S19A)
- Hydrapres® 20 mg AMP 1 mL x 5 (SAS).
The S19A and SAS alternatives are identical in active ingredient and strength to the Australian-registered product. However, there are differences in excipients and reconstitution requirements. Healthcare professionals should check the product carefully before use.
Normal supplies of Apresoline® ampoules are expected to resume by the end of March 2026.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates